|
|
Biography
Sandra Degen, PhD, was appointed vice president for research at the University of Cincinnati in November 2005 after having served as acting vice president since September 2004.
Degen is responsible for the oversight and strategic development of the university's research mission, which in fiscal year 2008 received more than $353 million in funding, placing it among the top public universities for federal research expenditures. She also is responsible for supervision of research compliance, technology transfer, entrepreneurial affairs and sponsored programs.
Degen is professor of pediatrics and associate chair for academic affairs in the University of Cincinnati College of Medicine's department of pediatrics. She has served in the Academic Health Center provost's office as associate senior vice president for health affairs.
After receiving a PhD in biochemistry from the University of Washington, Degen completed two years of postdoctoral work at the Friedrich Miescher Institute, Basel, Switzerland. She joined the faculty and staff of the College of Medicine and Cincinnati Children's Research Foundation in 1985.
A Pew Scholar in the biomedical sciences, Degen's scientific interests include the biological function of the blood coagulation agent prothrombin, as well as a protein identified in her lab that is involved in growth control. Degen holds three patents for her discoveries.
Degen is member of several boards, including TechSolve, BioStart, Ohio Aerospace Institute, Ohio Supercomputer, Oak Ridge Associated Universities (ORAU). In March 2007, she was elected vice chair of the Council of Sponsoring Institutions of ORAU.
Her many honors include an Established Investigatorship from the American Heart Association, membership of the Hematology II Study Section at the National Institutes of Health, and participation in the Executive Leadership in Academic Medicine Program. She was awarded the 2005 Special Recognition Award in Thrombosis from the American Heart Association.
